Plasmapheresis, immunosuppressive therapy and anti-GBM disease prognosis: a cohort study of 107 patients
| Autor: | Ying Liu, Yiting Wu, Wei Wei, Letian Yang, Caihong Liu, Jian Li, Yongxiu Huang, Bo Wang, Yingying Yang, Ling Zhang, Ping Fu, Yuliang Zhao |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2024 |
| Předmět: | |
| Zdroj: | Renal Failure, Vol 46, Iss 2 (2024) |
| Druh dokumentu: | article |
| ISSN: | 0886022X 1525-6049 0886-022X |
| DOI: | 10.1080/0886022X.2024.2400539 |
| Popis: | Background Anti-glomerular basement membrane (anti-GBM) disease presents with rapidly progressive glomerulonephritis and alveolar hemorrhage, requiring urgent management. In this study, we analyzed the relationship between plasmapheresis strategy, immunosuppressive therapy and the prognosis of anti-GBM disease patients.Method We screened newly diagnosed anti-GBM disease patients at West China Hospital of Sichuan University from 2010 to 2021. The primary outcome was a composite endpoint of in-hospital death or dialysis dependency upon discharge.Results This study enrolled 107 anti-GBM disease patients. The use of plasmapheresis was independently associated with a reduced risk of primary outcome (OR: 0.179, 95% Cl: 0.051–0.630, p = 0.007), better 2-year (HR: 0.146; 95% CI: 0.038–0.553; p = 0.005) and 8-year patient survival (HR: 0.309; 95% CI: 0.112–0.850; p = 0.023). Restricted cubic spline regression suggested that patients with 5–10 sessions of plasmapheresis had already achieved maximum risk reduction in the primary outcome. Patients who started plasmapheresis at lower serum creatinine (42.9% vs. 96.2%, p |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|